Production resumes at troubled Abbott baby formula factory
FILE – An Abbott Laboratories manufacturing plant is shown in Sturgis, Mich., on Sept. 23, 2010. Severe weather has forced Abbott Nutrition to pause production at a Michigan baby formula factory that had just restarted. The company said late Wednesday, June 15, 2022 that production for its EleCare specialty formula has stopped, but it has enough supply to meet needs until more formula can be made. (Brandon Watson/Sturgis Journal via AP)
ovp test
Male shot by female at Shreveport apartment
Class to create biodiverse backyard
Rules for outbursts at Caddo School Board Meeting
STURGIS, Mich. (AP) — Production of baby formula has resumed at the Michigan Abbott Nutrition factory whose February shutdown over contamination contributed to a national shortage, a company spokesman said.
Damage from severe thunderstorms, including flooding, had forced the Sturgis plant to halt operations in mid-June just two weeks after restarting production with additional sanitizing and safety protocols.
Production of EleCare, a specialty formula for infants with severe food allergies and digestive problems, was restored at Sturgis following a July 1 reboot, said Abbott spokesman John Koval.
“We are working to restart Similac production as soon as we can. We’ll provide more information when we have it,” he said via email.
Abbott recalled several leading brands of formula in February, including Similac. That squeezed supplies already strained by supply chain disruptions and stockpiling during COVID-19 shutdowns.
The shortage was most dire for children with allergies, digestive problems and metabolic disorders who rely on specialty formulas.
President Joe Biden’s administration has since eased import rules for foreign manufacturers, airlifted formula from Europe and invoked federal emergency rules to prioritize U.S. production.
Abbott is one of just four companies that produce about 90% of U.S. formula. Koval declined to say how much of Abbott’s overall U.S. supply of infant formula is produced at the Sturgis plant.
The plant was closed in February after the Food and Drug Administration began investigating four bacterial infections among infants who consumed powdered formula from the plant. Two of the babies died. The company says its products have not been directly linked to the infections, which involved different bacterial strains.
FDA inspectors eventually uncovered a host of violations at the plant, including bacterial contamination, a leaky roof and lax safety protocols.
On Wednesday, the Food and Drug Administration announced plans to help overseas makers of infant formula that have sent supplies, under emergency approval to address the shortfall, secure long-term authorization to market their formula in the U.S. The plan is to provide American consumers with more choices and make supplies more resilient against current or future shortages.
FDA Commissioner Dr. Robert Califf, and Susan Mayne, the director of the agency’s Center for Food Safety and Applied Nutrition, said in a statement that the Sturgis plant shutdown “compounded by unforeseen natural weather events, has shown just how vulnerable the supply chain has become.”
© 2022 Associated Press All rights reserved.
